Combat posttraumatic stress disorder, substance use disorders, and traumatic brain injury

Journal of Addiction Medicine

Volumn 3, Issue 4, 2009, Pages 179-188

  Brady, Kathleen T ^a,b   Tuerk, Peter ^b   Back, Sudie E ^a   Saladin, Michael E ^a   Waldrop, Angela E ^c   Myrick, Hugh ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Combat; Posttraumatic stress disorder; PTSD; Substance use disorders; TBI

Indexed keywords

EID: 76649129357     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3181aa244f     Document Type: Review

References (106)

1. Kulka R, Schlenger W, Fairbank J, et al. Description, Current Status, and Initial PTSD Prevalence Estimates. Final Report. Washington: Veterans Administration; 1988.
2. Keane T, Kaloupek D. Comorbid psychiatric disorders in PTSD. Ann N Y Acad Sci. 1998:24-32.
3. Breslau N, Davis GC, Andreski P, et al. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry. 1991;48:216-222.
4. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52: 1048-1060.
5. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
6. Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with posttraumatic stress disorder: A review of the literature. Am J Psychiatry. 2001;158:1184-1190.
7. Mental Health Advisory Team (MHAT)V. Operation Iraqi Freedom 06-08: Iraq, Operation Enduring Freedom 8: Afghanistan. Department of Defense Office of the Surgeon General Multi-National Force Iraq and Office of the Surgeon General United States Army Medical Command, 2008.
8. Hoge CW, McGurk D, Thomas JL, et al. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. N Engl J Med. 2008;358:453-463.
9. Bryant RA. Disentangling mild traumatic brain injury and stress reactions. N Engl J Med. 2008;358:525-527.
10. Substance Abuse and Mental Health Services Administration Office of Applied Services. The NSDUH report: Serious psychological distress and substance use among veterans. Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Services; 2007.
11. Substance Abuse and Mental Health Services Administration Office of Applied Services. Alcohol Use and Alcohol-related Risk Behaviors among Veterans. Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Services; 2005.
12. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627. (Pubitemid 40973437)
13. Milliken CS, Auchterlonie JL, Hoge CW. Longitudinal assessment of mental health problems among active and reserve component soldiers returning from the Iraq war. JAMA. 2007;298:2141-2148.
14. Grant BF, Stinson FS, Dawson DA, et al. Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:361-368.
15. Grant BF, Harford TC. Comorbidity between DSM-IV alcohol use disorders and major depression: Results of a national survey. Drug Alcohol Depend. 1995;39:197-206.
16. Smith TC, Ryan MA, Wingard DL, et al. New onset and persistent symptoms of post-traumatic stress disorder self-reported after deployment and combat exposures: Prospective population based US military cohort study. BMJ. 2008;336:366-371.
17. Rosenheck RA, Fontana AF. Recent trends in VA treatment of posttraumatic stress disorder and other mental disorders. Health Aff (Millwood). 2007;26:1720-1727.
18. Okie S. Traumatic brain injury in the war zone. N Engl J Med. 2005;352:2043-2047.
19. Guerrero JL, Thurman DJ, Sniezek JE. Emergency department visits associated with traumatic brain injury: United States, 1995-1996. Brain Inj. 2000;14:181-186.
20. Corrigan JD, Cole TB. Substance use disorders and clinical management of traumatic brain injury and posttraumatic stress disorder. JAMA. 2008;300:720-721.
21. Sarnyai Z, Biro E, Gardi J, et al. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res. 1995;675:89-97.
22. Merlo Pich E, Lorang M, Yeganeh M, et al. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci. 1995;15:5439-5447.
23. Adinoff B, Martin PR, Bone GH, et al. Hypothalamic-pituitary-adrenal axis functioning and cerebrospinal fluid corticotropin releasing hormone and corticotropin levels in alcoholics after recent and long-term abstinence. Arch Gen Psychiatry. 1990;47:325-330.
24. Baker DG, West SA, Nicholson WE, et al. Serial CSF corticotropinreleasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry. 1999;156:585-588.
25. Bremner JD, Licinio J, Darnell A, et al. Elevated CSF corticotropinreleasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry. 1997;154:624-629.
26. Swerdlow NR, Britton KT, Koob GF. Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9-41). Neuropsychopharmacology. 1989;2:285-292.
27. Southwick SM, Bremner JD, Rasmusson A, et al. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;46:1192-1204.
28. Charney DS, Redmond DE Jr, Galloway MP, et al. Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: Evidence for noradrenergic hyperactivity. Life Sci. 1984;35:1263-1272.
29. Hawley RJ, Major LF, Schulman EA, et al. Cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol and norepinephrine levels in alcohol withdrawal. Correlations with clinical signs. Arch Gen Psychiatry. 1985;42:1056-1062.
30. Smith AJ, Brent PJ, Henry DA, et al. Plasma noradrenaline, platelet alpha 2-adrenoceptors, and functional scores during ethanol withdrawal. Alcohol Clin Exp Res. 1990;14:497-502.
31. Chappell PB, Smith MA, Kilts CD, et al. Alterations in corticotropinreleasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J Neurosci. 1986;6:2908-2914.
32. Zhang JJ, Swiergiel AH, Palamarchouk VS, et al. Intracerebroventricular infusion of CRF increases extracellular concentrations of norepinephrine in the hippocampus and cortex as determined by in vivo voltammetry. Brain Res Bull. 1998;47:277-284.
33. Lavicky J, Dunn AJ. Corticotropin-releasing factor stimulates catecholamine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis. J Neurochem. 1993;60:602-612.
34. Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry. 2007;164:1149-1159.
35. Jorge RE, Starkstein SE, Arndt S, et al. Alcohol misuse and mood disorders following traumatic brain injury. Arch Gen Psychiatry. 2005; 62:742-749.
36. Jorge RE. Neuropsychiatric consequences of traumatic brain injury: A review of recent findings. Curr Opin Psychiatry. 2005;18:289-299.
37. Graham DP, Cardon AL. An update on substance use and treatment following traumatic brain injury. Ann NY Acad Sci. 2008;1141:148-162.
38. Lux WE. A neuropsychiatric perspective on traumatic brain injury. J Rehabil Res Dev. 2007;44:951-962.
39. Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: Brain circuits and treatment strategies. Neuropharmacology. 2004;47 (Suppl 1):3-13.
40. Volkow ND, Fowler JS, Wang GJ. The addicted human brain: Insights from imaging studies. J Clin Invest. 2003;111:1444-1451.
41. Parry-Jones BL, Vaughan FL, Miles Cox W. Traumatic brain injury and substance misuse: A systematic review of prevalence and outcomes research (1994 -2004). Neuropsychol Rehabil. 2006;16:537-560.
42. Schutzwohl M, Maercker A. Effects of varying diagnostic criteria for posttraumatic stress disorder are endorsing the concept of partial PTSD. J Trauma Stress. 1999;12:155-165.
43. Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. Am J Psychiatry. 2001;158:1982-1988.
44. Matthews LR, Chinnery D. Prediction of work functioning following accidental injury: The contribution of PTSD symptom severity and other established risk factors. Int J Psychol. 2005;40:339-348.
45. Anthony MM, Orsillo SM, Roemer L. Practitioner's Guide to Empirically Based Measures of Anxiety. New York: Kluwer Academic/ Plenum Publishers; 2001.
46. Brewin CR. Systematic review of screening instruments for adults at risk of PTSD. J Trauma Stress. 2005;18:53-62.
47. Wilson JP, Keane TM. Assessing Psychological Trauma and PTSD. New York: Guilford Press; 1997.
48. Blake DD, Weathers FW, Nagy LM, et al. The Clinician Administered PTSD Scale-IV. National Center for Post-traumatic Stress Disorder, Behavioral Science Division-Boston, VA: Boston, MA; 1990.
49. Weathers FW, Keane TM, Davidson JR. Clinician-administered PTSD scale: A review of the first ten years of research. Depress Anxiety. 2001;13:132-156.
50. Blake DD, Weathers FW, Nagy LM, et al. The development of a clinician-administered PTSD scale. J Trauma Stress. 1995;8:75-90.
51. Kilpatrick D, Resnick H, Freedy J. The Potential Stressful Events Interview. Charleston: Medical University of South Carolina. In press.
52. Kilpatrick D, Resnick H, Saunders B, Best C. The National Women's Study PTSD Module. Charleston: Medical University of South Carolina. In press.
53. Keane TM, Caddell JM, Taylor KL. Mississippi scale for combatrelated posttraumatic stress disorder: Three studies in reliability and validity. J Consult Clin Psychol. 1998;56:85-90.
54. McFall ME, Smith DE, Roszell DK, et al. Convergent validity of measures of PTSD in Vietnam combat veterans. Am J Psychiatry. 1990;147:645-648.
55. Weathers FW, Hushka J, Keane TM. The PTSD Checklist Military Version (PCL-M). Boston: National Center for PTSD; 1991.
56. Weiss DS, Marmar CR. The impact of event scale-revised. In: Wilson JP, Keane TM, eds. Assessing Psychological Trauma and PTSD. New York: Guilford Press; 1997:399-411.
57. Baguena MJ, Villarroya E, Belena A, et al. Psychometric properties of the Spanish version of the Impact of Event Scale-Revised (IES-R). Analyisis y Modificacion de Conducta. 2001;27:581-604.
58. Asukai N, Kato H, Kawamura N, et al. Reliability and validity of the Japanese-language version of the impact of event scale-revised (IESR- J): four studies of different traumatic events. J Nerv Mental Disease. 2002;190:175-182.
59. Kazlauskas E, Gailiene D, Domanskaite-Gota V, et al. Psychometric properties of the lithuanian version of the impact of event scale-revised (IES-R). Psichologija. 2006;33:22-30.
60. Rash CJ, Coffey SF, Baschnagel JS, et al. Psychometric properties of the IES-R in traumatized substance dependent individuals with and without PTSD. Addict Behav. 2008;33:1039-1047.
61. Falsetti SA. The modified PTSD symptom scale: A brief self-report measure of posttraumatic stress disorder. Behav Ther. 1993;16:161-162.
62. Dansky BS, Saladin ME, Coffey SF, et al. Use of self-report measures of crime-related posttraumatic stress disorder with substance use disordered patients. J Subst Abuse Treat. 1997;14:431-437.
63. Coffey SF, Dansky BS, Falsetti SA, et al. Screening for PTSD in a substance abuse sample: Psychometric properties of a modified version of the PTSD Symptom Scale Self-Report. Posttraumatic stress disorder. J Trauma Stress. 1998;11:393-399.
64. Zohar J, Amital D, Miodownik C, et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol. 2002;22:190-195.
65. Friedman MJ, Marmar CR, Baker DG, et al. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007; 68:711-720.
66. Tucker P, Potter-Kimball R, Wyatt DB, et al. Can physiologic assessment and side effects tease out differences in PTSD trials? A doubleblind comparison of citalopram, sertraline, and placebo. Psychopharmacol Bull. 2003;37:135-149.
67. Davidson J, Pearlstein T, Londborg P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: Results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry. 2001; 158:1974-1981.
68. Brady K, Pearlstein T, Asnis G, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder. JAMA. 2000;283:1837-1844.
69. Martenyi F, Brown EB, Zhang H, et al. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 2002;63:199-206.
70. Brady KT, Sonne S, Anton RF, et al. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res. 2005;29:395-401.
71. Van Ameringen M, Mancini C, Pipe B, et al. Antiepileptic drugs in the treatment of anxiety disorders: Role in therapy. Drugs. 2004;64:2199-2220.
72. Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:201-206.
73. Johnson DR, Rosenheck R, Fontana A, et al. Outcome of intensive inpatient treatment for combat-related posttraumatic stress disorder. Am J Psychiatry. 1996;153:771-777. (Pubitemid 26170537)
74. Brodie JD, Figueroa E, Laska EM, et al. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005;55:122-125.
75. Reich DB, Winternitz S, Hennen J, et al. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry. 2004;65:1601-1606.
76. Bartzokis G, Lu PH, Turner J, et al. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 2005;57:474-479.
77. Kampman KM, Pettinati HM, Lynch KG, et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol. 2007;27:344-351.
78. Deb S, Crownshaw T. The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Inj. 2004;18:1-31.
79. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346-356.
80. Villegier AS, Lotfipour S, Belluzzi JD, et al. Involvement of alpha1-adrenergic receptors in tranylcypromine enhancement of nicotine selfadministration in rat. Psychopharmacology (Berl). 2007;193:457-465.
81. Greenwell TN, Walker BM, Cottone P, et al. The alpha1 adrenergic receptor antagonist prazosin reduces heroin self-administration in rats with extended access to heroin administration. Pharmacol Biochem Behav. 2009;91:295-302.
82. Darracq L, Blanc G, Glowinski J, et al. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of Damphetamine. J Neurosci. 1998;18:2729-2739.
83. Wee S, Mandyam CD, Lekic DM, et al. Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access. Eur Neuropsychopharmacol. 2008;18:303-311.
84. Simpson TL, Saxon AJ, Meredith CW, et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res. 2009;33:255-263.
85. Petrakis IL, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry. 2006;60:777-783.
86. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221-226.
87. Johnson RE, Strain EC, Amass L. Buprenorphine: How to use it right. Drug Alcohol Depend. 2003;70 (2 Suppl):S59-S77.
88. McFall M, Saxon AJ, Thompson CE, et al. Improving the rates of quitting smoking for veterans with posttraumatic stress disorder. Am J Psychiatry. 2005;162:1311-1319.
89. Young HE, Rosen CS, Finney JW. A survey of PTSD screening and referral practices in VA addiction treatment programs. J Subst Abuse Treat. 2005;28:313-319.
90. Najavits LM, Sullivan TP, Schmitz M, et al. Treatment utilization by women with PTSD and substance dependence. Am J Addict. 2004;13: 215-224.
91. Brown PJ, Stout RL, Gannon-Rowley J. Substance use disorder-PTSD comorbidity. Patients' perceptions of symptom interplay and treatment issues. J Subst Abuse Treat. 1998;15:445-448.
92. Back SE, Brady KT, Jaanimagi U, et al. Cocaine dependence and PTSD: A pilot study of symptom interplay and treatment preferences. Addict Behav. 2006;31:351-354.
93. McNally RJ. Mechanisms of exposure therapy: How neuroscience can improve psychological treatments for anxiety disorders. Clin Psychol Rev. 2007;27:750-759.
94. Najavits LM, Weiss RD, Shaw SR, et al. "Seeking safety": Outcome of a new cognitive-behavioral psychotherapy for women with posttraumatic stress disorder and substance dependence. J Trauma Stress. 1998;11:437-456.
95. Najavits LM. Seeking Safety: A treatment Manual for PTSD and Substance Abuse. New York: Guilford Press; 2002.
96. Hien DA, Cohen LR, Miele GM, et al. Promising treatments for women with comorbid PTSD and substance use disorders. Am J Psychiatry. 2004;161:1426-1432.
97. Najavits LM, Schmitz M, Gotthardt S, et al. Seeking safety plus exposure therapy: An outcome study on dual diagnosis men. J Psychoactive Drugs. 2005;37:425-435.
98. Weaver CM, Trafton JA, Walser RD, et al. Pilot test of seeking safety treatment with male veterans. Psychiatr Serv. 2007;58:1012-1013.
99. Triffleman E, Carroll K, Kellogg S. Substance dependence posttraumatic stress disorder therapy. An integrated cognitive-behavioral approach. J Subst Abuse Treat. 1999;17:3-14.
100. Triffleman E. Gender differences in a controlled pilot study of psychosocial treatments in substance dependent patients with post-traumatic stress disorder: Design considerations and outcomes. Alcohol Treat Q. 2000;18:113-126.
101. Brady KT, Dansky BS, Back SE, et al. Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: Preliminary findings. J Subst Abuse Treat. 2001;21:47-54.
102. Back SE, Dansky BS, Carroll KM, et al. Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: Description of procedures. J Subst Abuse Treat. 2001;21:35-45.
103. Mills KL, Teesson M, Back SE, et al. Integrated Treatment for Substance Use and PTSD Using Exposure Therapy: Preliminary Findings. San Juan, Puerto Rico: College on Problems of Drug Dependence; 2008.
104. Department of Veterans Affairs VHA. Health Program Guidelines for the New Veterans Health Administration. Washington: Department of Veterans Affairs, Veterans Health Administration; 1999.
105. Donovan B, Padin-Rivera E, Kowaliw S. "Transcend:" Initial outcomes from a posttraumatic stress disorder/substance abuse treatment program. J Trauma Stress. 2001;14:757-772.
106. Soo C, Tate R. Psychological treatment for anxiety in people with traumatic brain injury. Cochrane Database Syst Rev. 2007:CD005239.